Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model

Arthritis Research and Therapy

Volumn 14, Issue 6, 2012, Pages

  Tsuchida, Anika I ^a   Beekhuizen, Michiel ^a   Rutgers, Marijn ^a   van Osch, Gerjo J V M ^b   Bekkers, Joris E J ^a   Bot, Arjan G J ^a   Geurts, Bernd ^a   Dhert, Wouter J A ^a,c   Saris, Daniel B F ^a,d   Creemers, Laura B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DNA; GLYCOSAMINOGLYCAN; INTERLEUKIN 6; TOCILIZUMAB;

ADULT; ARTICLE; BONE METABOLISM; BONE REGENERATION; CARTILAGE CELL; CARTILAGE INJURY; CELL CULTURE; CELL ISOLATION; CELL REGENERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IN VITRO STUDY; OSTEOARTHRITIS; PROTEIN SECRETION; SYNOVIAL FLUID; AGED; ANTAGONISTS AND INHIBITORS; ARTICULAR CARTILAGE; BIOLOGICAL MODEL; CHONDROGENESIS; DRUG EFFECTS; EXTRACELLULAR MATRIX; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; REGENERATION; TISSUE CULTURE TECHNIQUE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; CHONDROGENESIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GLYCOSAMINOGLYCANS; HUMANS; INTERLEUKIN-6; MIDDLE AGED; MODELS, BIOLOGICAL; OSTEOARTHRITIS; REGENERATION; SYNOVIAL FLUID; TISSUE CULTURE TECHNIQUES; YOUNG ADULT;

EID: 84870302401     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4107     Document Type: Article

References (79)

1. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011, 23:471-478. 10.1097/BOR.0b013e328349c2b1, 21788902.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219. 10.1056/NEJMra1004965, 22150039.
3. Liang B, Song Z, Wu B, Gardner D, Shealy D, Song XY, Wooley PH. Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis. J Inflamm (Lond) 2009, 6:10.
4. Jazayeri JA, Carroll GJ, Vernallis AB. Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists. Int Immunopharmacol 2010, 10:1-8. 10.1016/j.intimp.2009.09.019, 19804846.
5. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:625-639.
6. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011, 63:609-621. 10.1002/art.30158, 21360490.
7. Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, Nishimoto N. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol 2011, 21:10-15. 10.1007/s10165-010-0325-3, 3036807, 20574648.
8. Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010, 62:33-43. 10.1002/art.25053, 20039425.
9. Gobezie R, Kho A, Krastins B, Sarracino DA, Thornhill TS, Chase M, Millett PJ, Lee DM. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther 2007, 9:R36. 10.1186/ar2172, 1906814, 17407561.
10. Kokebie R, Aggarwal R, Lidder S, Hakimiyan AA, Rueger DC, Block JA, Chubinskaya S. The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors. Arthritis Res Ther 2011, 13:R50. 10.1186/ar3293, 3132039, 21435227.
11. Scanzello CR, Umoh E, Pessler F, Diaz-Torne C, Miles T, Dicarlo E, Potter HG, Mandl L, Marx R, Rodeo S, Goldring SR, Crow MK. Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease. Osteoarthritis Cartilage 2009, 17:1040-1048. 10.1016/j.joca.2009.02.011, 19289234.
12. Regan EA, Bowler RP, Crapo JD. Joint fluid antioxidants are decreased in osteoarthritic joints compared to joints with macroscopically intact cartilage and subacute injury. Osteoarthritis Cartilage 2008, 16:515-521. 10.1016/j.joca.2007.09.001, 18203633.
13. Doss F, Menard J, Hauschild M, Kreutzer HJ, Mittlmeier T, Muller-Steinhardt M, Muller B. Elevated IL-6 levels in the synovial fluid of osteoarthritis patients stem from plasma cells. Scand J Rheumatol 2007, 36:136-139. 10.1080/03009740701250785, 17476620.
14. Ushiyama T, Chano T, Inoue K, Matsusue Y. Cytokine production in the infrapatellar fat pad: another source of cytokines in knee synovial fluids. Ann Rheum Dis 2003, 62:108-112. 10.1136/ard.62.2.108, 1754438, 12525378.
15. Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, Dayer JM, Vischer T, Guerne PA. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 1997, 24:1510-1516.
16. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996, 11:88-95.
17. Stannus O, Jones G, Cicuttini F, Parameswaran V, Quinn S, Burgess J, Ding C. Circulating levels of IL-6 and TNF-alpha are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage 2010, 18:1441-1447. 10.1016/j.joca.2010.08.016, 20816981.
18. Livshits G, Zhai G, Hart DJ, Kato BS, Wang H, Williams FM, Spector TD. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: the Chingford Study. Arthritis Rheum 2009, 60:2037-2045. 10.1002/art.24598, 2841820, 19565477.
19. Cuellar VG, Cuellar JM, Golish SR, Yeomans DC, Scuderi GJ. Cytokine profiling in acute anterior cruciate ligament injury. Arthroscopy 2010, 26:1296-1301. 10.1016/j.arthro.2010.02.011, 20887928.
20. Elsaid KA, Fleming BC, Oksendahl HL, Machan JT, Fadale PD, Hulstyn MJ, Shalvoy R, Jay GD. Decreased lubricin concentrations and markers of joint inflammation in the synovial fluid of patients with anterior cruciate ligament injury. Arthritis Rheum 2008, 58:1707-1715. 10.1002/art.23495, 2789974, 18512776.
21. Catterall JB, Stabler TV, Flannery CR, Kraus VB. Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254). Arthritis Res Ther 2010, 12:R229. 10.1186/ar3216, 3046542, 21194441.
22. Cuellar JM, Scuderi GJ, Cuellar VG, Golish SR, Yeomans DC. Diagnostic utility of cytokine biomarkers in the evaluation of acute knee pain. J Bone Joint Surg Am 2009, 91:2313-2320. 10.2106/JBJS.H.00835, 19797564.
23. Vanlauwe J, Saris DB, Victor J, Almqvist KF, Bellemans J, Luyten FP, . TIG/ACT/01/2000&EXT Study Group Five-year outcome of characterized chondrocyte implantation versus microfracture for symptomatic cartilage defects of the knee: early treatment matters. Am J Sports Med 2011, 39:2566-2574. 10.1177/0363546511422220, 21908720, TIG/ACT/01/2000&EXT Study Group.
24. Yang KG, Saris DB, Verbout AJ, Creemers LB, Dhert WJ. The effect of synovial fluid from injured knee joints on in vitro chondrogenesis. Tissue Eng 2006, 12:2957-2964. 10.1089/ten.2006.12.2957, 17518663.
25. Rodrigo JJ, Steadman JR, Syftestad G, Benton H, Silliman J. Effects of human knee synovial fluid on chondrogenesis in vitro. Am J Knee Surg 1995, 8:124-129.
26. Beekhuizen M, Bastiaansen-Jenniskens YM, Koevoet W, Saris DB, Dhert WJ, Creemers LB, van Osch GJ. Osteoarthritic synovial tissue inhibition of proteoglycan production in human osteoarthritic knee cartilage: establishment and characterization of a long-term cartilage-synovium coculture. Arthritis Rheum 2011, 63:1918-1927. 10.1002/art.30364, 21437876.
27. Calamia V, Rocha B, Mateos J, Fernandez-Puente P, Ruiz-Romero C, Blanco FJ. Metabolic labeling of chondrocytes for the quantitative analysis of the interleukin-1-beta-mediated modulation of their intracellular and extracellular proteomes. J Proteome Res 2011, 10:3701-3711. 10.1021/pr200331k, 21692455.
28. Henrotin YE, De Groote DD, Labasse AH, Gaspar SE, Zheng SX, Geenen VG, Reginster JY. Effects of exogenous IL-1 beta, TNF alpha, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes. Osteoarthritis Cartilage 1996, 4:163-173. 10.1016/S1063-4584(96)80012-4, 8895217.
29. Guerne PA, Carson DA, Lotz M. IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J Immunol 1990, 144:499-505.
30. Fan Z, Bau B, Yang H, Aigner T. IL-1beta induction of IL-6 and LIF in normal articular human chondrocytes involves the ERK, p38 and NFkappaB signaling pathways. Cytokine 2004, 28:17-24. 10.1016/j.cyto.2004.06.003, 15341921.
31. Wang P, Zhu F, Konstantopoulos K. Prostaglandin E2 induces interleukin-6 expression in human chondrocytes via cAMP/protein kinase A- and phosphatidylinositol 3-kinase-dependent NF-kappaB activation. Am J Physiol Cell Physiol 2010, 298:C1445-1456. 10.1152/ajpcell.00508.2009, 2889633, 20457835.
32. Klatt AR, Paul-Klausch B, Klinger G, Kuhn G, Renno JH, Banerjee M, Malchau G, Wielckens K. A critical role for collagen II in cartilage matrix degradation: collagen II induces pro-inflammatory cytokines and MMPs in primary human chondrocytes. J Orthop Res 2009, 27:65-70. 10.1002/jor.20716, 18655132.
33. Klatt AR, Zech D, Kuhn G, Paul-Klausch B, Klinger G, Renno JH, Schmidt J, Malchau G, Wielckens K. Discoidin domain receptor 2 mediates the collagen II-dependent release of interleukin-6 in primary human chondrocytes. J Pathol 2009, 218:241-247. 10.1002/path.2529, 19267386.
34. Sims NA, Walsh NC. GP130 cytokines and bone remodelling in health and disease. BMB Rep 2010, 43:513-523. 10.5483/BMBRep.2010.43.8.513, 20797312.
35. Schaible HG, von Banchet GS, Boettger MK, Brauer R, Gajda M, Richter F, Hensellek S, Brenn D, Natura G. The role of proinflammatory cytokines in the generation and maintenance of joint pain. Ann N Y Acad Sci 2010, 1193:60-69. 10.1111/j.1749-6632.2009.05301.x, 20398009.
36. Namba A, Aida Y, Suzuki N, Watanabe Y, Kawato T, Motohashi M, Maeno M, Matsumura H, Matsumoto M. Effects of IL-6 and soluble IL-6 receptor on the expression of cartilage matrix proteins in human chondrocytes. Connect Tissue Res 2007, 48:263-270. 10.1080/03008200701587513, 17882702.
37. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem 2003, 278:2903-2912. 10.1074/jbc.M110773200, 12419823.
38. Poree B, Kypriotou M, Chadjichristos C, Beauchef G, Renard E, Legendre F, Melin M, Gueret S, Hartmann DJ, Mallein-Gerin F, Pujol JP, Boumediene K, Galéra P. Interleukin-6 (IL-6) and/or soluble IL-6 receptor down-regulation of human type II collagen gene expression in articular chondrocytes requires a decrease of Sp1.Sp3 ratio and of the binding activity of both factors to the COL2A1 promoter. J Biol Chem 2008, 283:4850-4865.
39. Guerne PA, Desgeorges A, Jaspar JM, Relic B, Peter R, Hoffmeyer P, Dayer JM. Effects of IL-6 and its soluble receptor on proteoglycan synthesis and NO release by human articular chondrocytes: comparison with IL-1. Modulation by dexamethasone. Matrix Biol 1999, 18:253-260. 10.1016/S0945-053X(99)00021-9, 10429944.
40. Flannery CR, Little CB, Hughes CE, Curtis CL, Caterson B, Jones SA. IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol 2000, 19:549-553. 10.1016/S0945-053X(00)00111-6, 11068209.
41. Rogerson FM, Chung YM, Deutscher ME, Last K, Fosang AJ. Cytokine-induced increases in ADAMTS-4 messenger RNA expression do not lead to increased aggrecanase activity in ADAMTS-5-deficient mice. Arthritis Rheum 2010, 62:3365-3373. 10.1002/art.27661, 20662062.
42. de Hooge AS, van de Loo FA, Bennink MB, Arntz OJ, de Hooge P, van den Berg WB. Male IL-6 gene knock out mice developed more advanced osteoarthritis upon aging. Osteoarthritis Cartilage 2005, 13:66-73. 10.1016/j.joca.2004.09.011, 15639639.
43. Ryu JH, Yang S, Shin Y, Rhee J, Chun CH, Chun JS. Interleukin-6 plays an essential role in hypoxia-inducible factor 2alpha-induced experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum 2011, 63:2732-2743. 10.1002/art.30451, 21590680.
44. Sanchez C, Deberg MA, Burton S, Devel P, Reginster JY, Henrotin YE. Differential regulation of chondrocyte metabolism by oncostatin M and interleukin-6. Osteoarthritis Cartilage 2004, 12:801-810. 10.1016/j.joca.2004.06.011, 15450530.
45. Ley C, Svala E, Nilton A, Lindahl A, Eloranta ML, Ekman S, Ski Ldebrand E. Effects of high mobility group box protein-1, interleukin-1β, and interleukin-6 on cartilage matrix metabolism in three-dimensional equine chondrocyte cultures. Connect Tissue Res 2011, 52:290-300. 10.3109/03008207.2010.523803, 21117899.
46. McNulty AL, Miller MR, O'Connor SK, Guilak F. The effects of adipokines on cartilage and meniscus catabolism. Connect Tissue Res 2011, 52:523-533. 10.3109/03008207.2011.597902, 21787135.
47. [Dutch federation of Biomedical Scientific Societies]. , http://www.federa.org
48. van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. For. BMJ 2002, 325:648-651. 10.1136/bmj.325.7365.648, 12269316.
49. Bekkers JE, Saris DB, Tsuchida AI, van Rijen M, Dhert WJ, Creemers LB. Chondrogenic potential of articular chondrocytes depends on their original location. [Submitted for publication.].
50. de Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods 2005, 300:124-135. 10.1016/j.jim.2005.03.009, 15896801.
51. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003, 10:133-139. 145264, 12522051.
52. Nordan RP, Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986, 233:566-569. 10.1126/science.3726549, 3726549.
53. Rowan AD, Koshy PJ, Shingleton WD, Degnan BA, Heath JK, Vernallis AB, Spaull JR, Life PF, Hudson K, Cawston TE. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum 2001, 44:1620-1632. 10.1002/1529-0131(200107)44:7<1620::AID-ART285>3.0.CO;2-B, 11465713.
54. Farndale RW, Sayers CA, Barrett AJ. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res 1982, 9:247-248. 10.3109/03008208209160269, 6215207.
55. Heldens GT, Davidson EN, Vitters EL, Schreurs BW, Piek E, Berg WB, Kraan PM. Catabolic factors and osteoarthritis-conditioned medium inhibit chondrogenesis of human mesenchymal stem cells. Tissue Eng Part A 2012, 18:45-54.
56. Maiotti M, Monteleone G, Tarantino U, Fasciglione GF, Marini S, Coletta M. Correlation between osteoarthritic cartilage damage and levels of proteinases and proteinase inhibitors in synovial fluid from the knee joint. Arthroscopy 2000, 16:522-526. 10.1053/jars.2000.4632, 10882449.
57. Klein-Wieringa IR, Kloppenburg M, Bastiaansen-Jenniskens YM, Yusuf E, Kwekkeboom JC, El-Bannoudi H, Nelissen RG, Zuurmond A, Stojanovic-Susulic V, Van Osch GJ, Toes RE, Joan-Facsinay A. The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype. Ann Rheum Dis 2011, 70:851-857. 10.1136/ard.2010.140046, 21242232.
58. Distel E, Cadoudal T, Durant S, Poignard A, Chevalier X, Benelli C. The infrapatellar fat pad in knee osteoarthritis: an important source of interleukin-6 and its soluble receptor. Arthritis Rheum 2009, 60:3374-3377. 10.1002/art.24881, 19877065.
59. Hui W, Bell M, Carroll G. Oncostatin M (OSM) stimulates resorption and inhibits synthesis of proteoglycan in porcine articular cartilage explants. Cytokine 1996, 8:495-500. 10.1006/cyto.1996.0067, 8818547.
60. Silacci P, Dayer JM, Desgeorges A, Peter R, Manueddu C, Guerne PA. Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity. J Biol Chem 1998, 273:13625-13629. 10.1074/jbc.273.22.13625, 9593700.
61. Long D, Blake S, Song XY, Lark M, Loeser RF. Human articular chondrocytes produce IL-7 and respond to IL-7 with increased production of matrix metalloproteinase-13. Arthritis Res Ther 2008, 10:R23. 10.1186/ar2376, 2374453, 18289383.
62. Wang P, Zhu F, Lee NH, Konstantopoulos K. Shear-induced interleukin-6 synthesis in chondrocytes: roles of E prostanoid (EP) 2 and EP3 in cAMP/protein kinase A- and PI3-K/Akt-dependent NF-kappaB activation. J Biol Chem 2010, 285:24793-24804. 10.1074/jbc.M110.110320, 2915715, 20516073.
63. Pulai JI, Chen H, Im HJ, Kumar S, Hanning C, Hegde PS, Loeser RF. NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments. J Immunol 2005, 174:5781-5788. 2903737, 15843581.
64. Hashizume M, Mihara M. Desirable effect of combination therapy with high molecular weight hyaluronate and NSAIDs on MMP production. Osteoarthritis Cartilage 2009, 17:1513-1518. 10.1016/j.joca.2009.04.018, 19447215.
65. Villiger PM, Kusari AB, ten Dijke P, Lotz M. IL-1 beta and IL-6 selectively induce transforming growth factor-beta isoforms in human articular chondrocytes. J Immunol 1993, 151:3337-3344.
66. Hashizume M, Hayakawa N, Suzuki M, Mihara M. IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int 2009, 29:1449-1454. 10.1007/s00296-009-0885-8, 19277666.
67. De Benedetti F. The impact of chronic inflammation on the growing skeleton: lessons from interleukin-6 transgenic mice. Horm Res 2009, 72(Suppl 1):26-29.
68. Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine 2010, 77:201-205. 10.1016/j.jbspin.2010.03.002, 20444632.
69. van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995, 38:164-172. 10.1002/art.1780380204, 7848306.
70. van de Loo FA, Kuiper S, van Enckevort FH, Arntz OJ, van den Berg WB. Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice. Am J Pathol 1997, 151:177-191. 1857913, 9212744.
71. Klop C, de Vries F, Lalmohamed A, Mastbergen SC, Leufkens HG, Noort-van der Laan WH, Bijlsma JW, Welsing PM. COX-2-selective NSAIDs and risk of hip or knee replacements: a population-based case-control study. Calcif Tissue Int 2012, 91:387-394. 10.1007/s00223-012-9646-x, 23052224.
72. Heir S, Nerhus TK, Rotterud JH, Loken S, Ekeland A, Engebretsen L, Aroen A. Focal cartilage defects in the knee impair quality of life as much as severe osteoarthritis: a comparison of knee injury and osteoarthritis outcome score in 4 patient categories scheduled for knee surgery. Am J Sports Med 2010, 38:231-237. 10.1177/0363546509352157, 20042546.
73. Rubenhagen R, Schuttrumpf JP, Sturmer KM, Frosch KH. Interleukin-7 levels in synovial fluid increase with age and MMP-1 levels decrease with progression of osteoarthritis. Acta Orthop 2012, 83:59-64. 10.3109/17453674.2011.645195, 3278659, 22206448.
74. Pallante AL, Bae WC, Chen AC, Gortz S, Bugbee WD, Sah RL. Chondrocyte viability is higher after prolonged storage at 37 degrees C than at 4 degrees C for osteochondral grafts. Am J Sports Med 2009, 37(Suppl 1):24S-32S. 2858049, 19861697.
75. Lasczkowski GE, Aigner T, Gamerdinger U, Weiler G, Bratzke H. Visualization of postmortem chondrocyte damage by vital staining and confocal laser scanning 3D microscopy. J Forensic Sci 2002, 47:663-666.
76. Drobnic M, Mars T, Alibegovic A, Bole V, Balazic J, Grubic Z, Brecelj J. Viability of human chondrocytes in an ex vivo model in relation to temperature and cartilage depth. Folia Biol (Praha) 2005, 51:103-108.
77. Madea B, Kreuser C, Banaschak S. Postmortem biochemical examination of synovial fluid--a preliminary study. Forensic Sci Int 2001, 118:29-35. 10.1016/S0379-0738(00)00372-8, 11343852.
78. Tumram NK, Bardale RV, Dongre AP. Postmortem analysis of synovial fluid and vitreous humour for determination of death interval: a comparative study. Forensic Sci Int 2011, 204:186-190. 10.1016/j.forsciint.2010.06.007, 20638804.
79. Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V. Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin. Cytokine 2000, 12:1712-1716. 10.1006/cyto.2000.0764, 11052823.